Mingjie Zhang

Mingjie Zhang

Auto-generated profile, based on publicly available information

Mingjie Zhang

Chinese PLA General Hospital

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
MZMingjie Zhang
Mingjie Zhang
YLYufei Liu
Yufei Liu
MZMangsuo Zhao
Mangsuo Zhao
WTWenjing Tang
Wenjing Tang
XWXiaolin Wang
Xiaolin Wang
SYShengyuan Yu
Shengyuan Yu
Epidemiological and clinical studies have demonstrated comorbidity between migraine and affective disorders. However, it is unclear whether chronic migraine can lead to affective disorders in other animals. A classical chronic migraine rat model (repeated dura mater inflammatory soup [IS] infusion) was used to evaluate depression and anxiety behaviour via weight, sucrose preference test, open field test and elevated plus maze test. We found that sucrose preference, locomotor and rearing behaviours, inner zoon distance percent, open-arm entries percent and serotonin and dopamine levels in the prefrontal cortex decreased significantly in the IS group compared with those in the control group; co-administration of low-dose amitriptyline ameliorated these deficits. However, no differences in weight, inner zone time percent, or open-arm time percent between the IS and control groups. These results were used to create new depression and anxiety scales to comprehensively assess and evaluate the degree of affective disorders in rats. Most of chronic migraine animals showed depression and anxiety like behaviors but a few didn’t. Most of the chronic migraine rats were present depression and anxiety like behaviors. The new scales we created are expected to use in the future studies to find out the potential mechanism of affective disorders’ comorbidity.

25 March 2014 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
SYShengyuan Yu
Shengyuan Yu
MZMingjie Zhang
Mingjie Zhang
JZJiying Zhou
Jiying Zhou
RLRuozhuo Liu
Ruozhuo Liu
QWQi Wan
Qi Wan
YLYansheng Li
Yansheng Li

1 September 2013 in Neuroscience Letters
Verified
Journal Article
Closed access
MZMingjie Zhang
Mingjie Zhang
WDWei Dai
Wei Dai
JLJingyao Liang
Jingyao Liang
XCXiaoyan Chen
Xiaoyan Chen
YHYueqing Hu
Yueqing Hu
SYShengyuan Yu
Shengyuan Yu

24 February 2022 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
YTYue Tao
Yue Tao
FHFabienne Heskia
Fabienne Heskia
MZMingjie Zhang
Mingjie Zhang
RQRong Qin
Rong Qin
BKBin Kang
Bin Kang
ZXZhuoming Xu
Zhuoming Xu

9 October 2025 in Cephalalgia
Verified
Journal Article
Open access
MZMingjie Zhang
Mingjie Zhang
AGAihong Guo
Aihong Guo
JWJin Wu
Jin Wu
HWHebo Wang
Hebo Wang
YZYongbo Zhang
Yongbo Zhang
SYShengyuan Yu
Shengyuan Yu
Background: This study evaluated the long-term safety, tolerability and effectiveness of rimegepant, 75 mg orally disintegrating tablet, for the acute treatment of migraine in Chinese adults. Methods: This phase 3, multicenter, open-label, single-arm study enrolled Chinese adults with a ≥1 year history of migraine (with or without aura), 6–18 moderate-to-severe migraine attacks/month within three months before a screening visit and at least six migraine days during a 30-day observation phase (OP). After the OP, eligible participants took rimegepant as needed (maximum one tablet per day) at the onset of mild-to-severe migraine attack for a long-term treatment (LTT) of 52 weeks. Results: Overall, 240 participants were treated and 208 (86.3%) completed the study. During LTT, 203 (84.6%) participants reported ≥1 treatment-emergent adverse event (TEAE) and 46 (19.2%) reported ≥1 TEAE considered to be rimegepant-related. There were no rimegepant-related serious AEs or rimegepant-related TEAEs that led to treatment interruption or discontinuation. Mean reduction from the OP in monthly migraine days was observed as early as the first four weeks (−1.7; 95% confidence interval = −2.2 to −1.2), with an overall mean reduction of −4.4 (95% confidence interval = −4.9 to −3.9) days across LTT. Conclusions: Rimegepant had a favorable long-term safety profile, was well tolerated in Chinese participants, and a reduction in the number of monthly migraine days was observed during the LLT. Trial registration: ClinicalTrials.gov identifier: NCT05371652

7 September 2020 in International Journal of Neuroscience
Verified
Journal Article
Closed access
MZMangsuo Zhao
Mangsuo Zhao
MZMingjie Zhang
Mingjie Zhang
SZShimei Zhou
Shimei Zhou
BSBingxin Shi
Bingxin Shi
WYWei Yan
Wei Yan
LQLiyan Qiao
Liyan Qiao
Only five patients diagnosed with transverse myelitis (TM) associated with primary biliary cirrhosis (PBC) have been reported in the literature to date. We report two additional patients with TM as...